Deferiprone not beneficial for newly diagnosed Parkinson's disease

Deferiprone not beneficial for newly diagnosed parkinson disease

For patients newly diagnosed with Parkinson disease, deferiprone is associated with worse scores in measures of parkinsonism, according to a study published in the Dec. 1 issue of the New England Journal of Medicine.

David Devos, M.D., Ph.D., from the University of Lille in France, and colleagues conducted a 2 trial involving patients with newly diagnosed Parkinson disease who had never received levodopa. Participants were randomly assigned to receive oral deferiprone (15 mg/kg body weight twice daily) or matched placebo for 36 weeks in a 1:1 ratio (186 in each group). Unless deemed necessary for symptom control, dopaminergic therapy was withheld.

The researchers found that progression of symptoms led to initiation of dopaminergic therapy in 22.0 and 2.7 percent of participants in the deferiprone and placebo groups, respectively. The mean Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale score at baseline was 34.3 in the deferiprone group and 33.2 in the and increased by 15.6 and 6.3 points, respectively.

There was a greater decrease observed in nigrostriatal iron content in the deferiprone versus placebo group. The main serious adverse events with deferiprone were agranulocytosis and neutropenia in two and three participants, respectively.

"Deferiprone was not associated with benefit as compared with placebo in measures of the progression of Parkinson's disease, and there was evidence of clinical worsening," the authors write. "Deferiprone was associated with adverse events."

ApoPharma and Chiesi provided deferiprone and placebo for the study.

More information: David Devos et al, Trial of Deferiprone in Parkinson's Disease, New England Journal of Medicine (2022). DOI: 10.1056/NEJMoa2209254

Douglas Galasko et al, Lack of Benefit of Iron Chelation in Early Parkinson's Disease, New England Journal of Medicine (2022). DOI: 10.1056/NEJMe2213120

Journal information: New England Journal of Medicine

Copyright © 2022 HealthDay. All rights reserved.

Citation: Deferiprone not beneficial for newly diagnosed Parkinson's disease (2022, December 1) retrieved 31 May 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Monoclonal antibodies no better than placebo for early Parkinson disease


Feedback to editors